Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$ONTY http://bit.ly/1IROefe pg.2
$RLYP still holding mine kei.
That explains it. Thx.
Always was. My comment was shorts do what they want.
Shorts working on $FOMX again. Someone said shorts have to cover with good news this morning. BS...............
$TPIV
TapImmune Inc.
24,640,000 Shares of Common Stock
This prospectus supplement no. 1 supplements the prospectus dated August 7, 2015, which forms a part of our registration statement Form S-1 (Registration Statement No. 333-205757) relating to the resale of up to 24,640,000 shares of our common stock by the selling stockholders named in the “Selling Stockholders” section of the prospectus. We will not receive any proceeds from the sale of our shares by the selling stockholders.
This prospectus supplement is being filed to update and supplement the information included or incorporated by reference in the prospectus with the information contained in our Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on November 16, 2015 (the “Report”). Accordingly, we have attached the Report to this prospectus supplement.
The attached information amends and supplements certain information contained in the prospectus. This prospectus supplement is not complete without, and should not be delivered or utilized, except in conjunction with the prospectus, including any supplements and amendments thereto. You should read this prospectus supplement in conjunction with the prospectus, including any supplements and amendments thereto.
Our common stock is traded on the OTCQB marketplace under the symbol “TPIV.” On November 16, 2015, the last reported closing price of our common stock was $0.64 per share.
http://bit.ly/218ABUs
That's because most of the peeps posting here today are dumping. They'll stay quiet until it starts moving up again then start pumping it again. See this over and over.
I saw nothing about buying.
"relating to the sale of an aggregate of 3,409,629 of our common shares"
I'm not sure what this all means. Maybe ash111 might know.
$SPHS http://bit.ly/1Sn9zCu
Aspire Capital
Bears at work.
For whatever reason some people must not have liked what they read.
60% is great. You stated it in StockTwits.
Nov. 6 at 9:44 AM
JBEM
Josh McGuire
@Market_Fugazi 4 abstracts at ASH, this will be over $15 in a month.
I bought more while it was down this morning. Thanks for your reply. Go and enjoy your vaca w/family
It was a good call. Now I'm holding for the over $15 in a month he called on Nov. 6.
Board and jbem awfully quiet about $CALA.
Link?
Quiet board here. People still busy selling?
MEI Pharma Highlights New Data from Phase II Clinical Studies of Pracinostat in Acute Myeloid Leukemia and Myelodysplastic Syndrome
http://yhoo.it/1iFjqYb
I believe it's a mixed shelf.
Something Adam F didn't include in any of his articles about Firdapse.
"Catalyst’s Firdapse contains the phosphate salt of 3,4-DAP. The phosphate salt form is more stable than the free base form of the 3,4-DAP that is available from Jacobus. Catalyst CEO Patrick McEnany stressed that their 3,4-DAP is produced under all requirements of cGMP. If there were an approved drug by the FDA, most patients would have easy access to this drug."
Also this about Jacobus: "Even more serious is the cGMP defects of Jacobus in the past. The FDA issued 483 inspection reports for the Jacobus facility in 2011 and again in 2012 (read them here and here)."
http://bit.ly/1jUJK1M
Adam F up to his same old bullshit.
FDA warning on Viekira Pak.
https://pbs.twimg.com/media/CR8bf1oVAAAJaY2.png
$MEIP Posted by jbem this morning.
MEIP DD
Here is the link to my latest DD.
https://groups.google.com/forum/#!category-topic/jbem777/DD/g5S_xwJpOa4
$ZFGN I haven't read the news on it yet this morning but it makes sense.
Thanks Mort.
$TNXP I'm expecting same with data release this quarter. Don't know if he's still holding any.
$TNXP NEW YORK, June 16, 2015 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) ("Tonix"), a clinical-stage company developing next-generation medicines for fibromyalgia, post-traumatic stress disorder, and episodic tension-type headache, today announced that it has begun randomizing patients into a Phase 2 clinical study of TNX-201 (dexisometheptene mucate) in episodic tension-type headache. The study is expected to enroll approximately 200 patients at nine clinical centers in the United States. Tonix plans to report top-line results from this study in the fourth quarter of 2015.
jembers that's a good question.
$SRPT $27.20 taking a beating last 8 trading days.
It will get worse if fda decides to put a clinical hold on this.
shorts covering and over 82% tute ownership.
$ZFGN Yeah a patient died in a late stage trial in obesity drug. Think there was some insider trading? LOL
$AVXLD Anavex Awarded Grant From The Michael J. Fox Foundation for Parkinson’s Research - See more at: http://globenewswire.com/news-release/2015/08/10/759225/0/en/Anavex-Awarded-Grant-From-The-Michael-J-Fox-Foundation-for-Parkinson-s-Research.html#sthash.rG3Tzl4H.dpuf
NEW YORK, Aug. 10, 2015 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX:AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain, and various types of cancer, today announced that it has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to develop ANAVEX 2-73 for the treatment of Parkinson’s disease.
The MJFF grant is expected to fully fund a preclinical study on the effect of ANAVEX 2-73 in a Parkinson’s disease animal model, which seeks to provide a solid dataset that will justify moving forward to clinical development in Parkinson’s. The study may also provide further evidence for the involvement of sigma-1 receptors in potentially disease-modifying therapies for Parkinson’s disease.
- See more at: http://globenewswire.com/news-release/2015/08/10/759225/0/en/Anavex-Awarded-Grant-From-The-Michael-J-Fox-Foundation-for-Parkinson-s-Research.html#sthash.rG3Tzl4H.dpuf
http://bit.ly/1VSxs5v
Nice. Thanks kei.
$DCTH resistance at .81. Any catalysts upcoming?
They're wanting cheap shares.
$SRPT -7.9% also tanking.
$COLL Collegium Provides Update on FDA Review of Xtampza(TM) ER, an Abuse-Deterrent Analgesic for the Treatment of Chronic Pain
CANTON, Mass., Oct. 12, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (COLL) today announced that the U.S. Food and Drug Administration (FDA) has advised Collegium that it will not be able to complete its review of the New Drug Application (NDA) for Xtampza(TM) ER (oxycodone) extended-release capsules by the Prescription Drug User Fee Act (PDUFA) action date of October 12, 2015.
http://yhoo.it/1NEerF5